Leadership Overview
Certara has 10 executives leading key functions including strategy, finance, technology, marketing, human resources, commercial operations, data sciences, and drug development solutions.
Driven by scientific advancement, Certara is dedicated to optimizing drug development through model-informed approaches, enhancing patient outcomes, and accelerating market access for life-saving therapies.
Driven by scientific advancement, Certara is dedicated to optimizing drug development through model-informed approaches, enhancing patient outcomes, and accelerating market access for life-saving therapies.
Leadership Roles at Certara
William Feehery - Chief Executive Officer
William Feehery, the Chief Executive Officer at Certara, directs the company's overarching strategy and operational execution. Feehery guides Certara's mission to advance drug development through its integrated software, AI platforms, and scientific consulting. Overseeing all business units, Feehery ensures alignment with the core strength in model-informed drug development (MIDD) and biosimulation technologies. This leadership involves optimizing clinical outcomes and accelerating the path from discovery to market access. By fostering innovation, William Feehery drives the company's impact on predicting drug behavior and improving patient therapies globally. Feehery's strategic vision shapes Certara's market position and commitment to scientific excellence.
Ron Keizer - Founder & Chief Executive Officer
Ron Keizer, the Founder & Chief Executive Officer at Certara, established the company's foundational principles and continues to shape its strategic direction. Keizer's leadership focuses on the integration of software, AI-driven platforms, and scientific consulting across the entire drug development lifecycle. Overseeing the company's long-term vision, Keizer champions the core strength in model-informed drug development (MIDD) and biosimulation technologies. This involves ensuring Certara's solutions effectively predict drug behavior and optimize clinical outcomes for clients worldwide. By driving innovation and strategic partnerships, Ron Keizer advances Certara's mission to accelerate the delivery of critical therapies to patients. Keizer's entrepreneurial spirit underpins Certara's commitment to scientific rigor and market leadership.
John Gallagher - Chief Financial Officer
John Gallagher, the Chief Financial Officer at Certara, directs all financial operations and strategic fiscal planning. Gallagher oversees the financial health of the organization, ensuring robust resource allocation for software development, AI platform expansion, and scientific consulting services. This role involves managing budgets, financial reporting, and investor relations, directly supporting Certara's model-informed drug development (MIDD) and biosimulation initiatives. By optimizing financial strategies, John Gallagher enables the company to effectively predict drug behavior and achieve its market access goals. Gallagher's financial acumen is critical for driving sustainable growth and maximizing the impact of Certara's technologies on clinical outcomes.
Leif Pedersen - President & Chief Commercial Officer
Leif Pedersen, the President & Chief Commercial Officer at Certara, directs global sales, business development, and commercial strategy. Pedersen oversees the go-to-market approach for Certara's comprehensive suite of software, AI-driven platforms, and scientific consulting services. This leadership role focuses on expanding market penetration and driving revenue growth by highlighting the benefits of model-informed drug development (MIDD) and biosimulation technologies. By forging strong client relationships, Leif Pedersen ensures that organizations effectively leverage Certara's solutions to predict drug behavior and optimize clinical outcomes. Pedersen's commercial leadership is instrumental in advancing Certara's mission to accelerate drug development worldwide.
Martin Snyder - President, Certara Data Sciences
Martin Snyder, the President, Certara Data Sciences at Certara, leads the strategic direction and operational execution of the company's data science initiatives. Snyder oversees the development and application of advanced analytics and AI to enhance drug development processes. This leadership role focuses on leveraging data to optimize biosimulation technologies and model-informed drug development (MIDD) strategies. By driving innovation in data science, Martin Snyder ensures Certara's clients can more effectively predict drug behavior and achieve superior clinical outcomes. Snyder's expertise is critical for advancing the company's capabilities in transforming complex data into actionable insights for pharmaceutical research and development.
Adrian McKemey - President, Certara Drug Development Solutions
Adrian McKemey, the President, Certara Drug Development Solutions at Certara, spearheads the company's comprehensive drug development consulting services. McKemey directs teams that provide scientific expertise across the entire lifecycle, from discovery through regulatory submissions and market access. This leadership role emphasizes the integration of software and AI platforms with expert scientific guidance, particularly in model-informed drug development (MIDD) and biosimulation. By optimizing development strategies, Adrian McKemey ensures clients can accurately predict drug behavior and achieve successful clinical outcomes. McKemey's focus on integrated solutions drives Certara's mission to accelerate the delivery of innovative therapies to patients globally.
Gregory Smith - Chief Technology Officer
Gregory Smith, the Chief Technology Officer at Certara, leads the technological vision and infrastructure development for the company's diverse offerings. Smith oversees the advancement of Certara's software solutions, AI-driven platforms, and the underlying technology supporting scientific consulting services. This critical role ensures the scalability and innovation of tools used across the drug development lifecycle, from discovery to market access. By driving technological innovation, Gregory Smith enhances the capabilities of model-informed drug development (MIDD) and biosimulation technologies. Smith's leadership ensures Certara's platforms effectively predict drug behavior and optimize clinical outcomes, solidifying the company's position at the forefront of pharmaceutical technology.
Sheila Rocchio - Chief Marketing Officer
Sheila Rocchio, the Chief Marketing Officer at Certara, drives the company's global marketing strategy and brand positioning. Rocchio oversees the promotion of Certara's software, AI-driven platforms, and scientific consulting services, emphasizing their role in optimizing drug development. This leadership position involves communicating the value of model-informed drug development (MIDD) and biosimulation technologies to a global audience. By crafting compelling narratives, Sheila Rocchio enhances market awareness and demand for solutions that predict drug behavior and improve clinical outcomes. Rocchio's strategic marketing initiatives are crucial for expanding Certara's reach and impact across the pharmaceutical and biotechnology sectors.
Rona Anhalt - Chief Human Resources Officer
Rona Anhalt, the Chief Human Resources Officer at Certara, leads the strategic development and execution of human capital initiatives. Anhalt oversees talent acquisition, employee development, and organizational culture, ensuring Certara attracts and retains top scientific and technical talent. This role is vital for supporting the company's expertise in software, AI platforms, and scientific consulting, particularly in model-informed drug development (MIDD) and biosimulation. By fostering a high-performance environment, Rona Anhalt enables the teams to effectively drive innovation in predicting drug behavior and optimizing clinical outcomes. Anhalt's focus on people ensures Certara's continued success in advancing drug development solutions.
Cynthia Collins - Member of the Board
Cynthia Collins, a Member of the Board at Certara, provides strategic oversight and governance to the executive leadership team. Collins contributes expertise in guiding the company's trajectory within the complex landscape of drug development services. This board-level role involves advising on critical decisions related to Certara's software, AI platforms, and scientific consulting offerings. By leveraging extensive industry experience, Cynthia Collins supports the company's focus on model-informed drug development (MIDD) and biosimulation technologies. Collins' guidance helps ensure Certara's continued impact on optimizing clinical outcomes and accelerating market access for new therapies. The board position ensures robust strategic direction and accountability for Certara's mission.
Explore Leadership Teams in Business Services
Founded in 2012, WCG measurably improves the quality and efficiency of clinical trials, helping biopharmaceutical companies, CROs, and institutions facilitate the development of new treatments and therapies for patients. The company is headquartered in Princeton, New Jersey.
Company Leadership SS
EC
The Jackson Laboratory is a nonprofit biomedical research institution focused on genetics and genomics research to understand and treat human disease. It develops mouse models, stem cell systems, and data-driven tools used by scientists worldwide for studying cancer, aging, neurological disorders, and other complex diseases.
Company Leadership EL
IW
LW
The Savannah River National Laboratory is a multi-program national laboratory for the U.S. Department of Energys Office of Environmental Management. SRNL is located at the Savannah River Site near Jackson, South Carolina. It was founded in 1951, as the Savannah River Laboratory. It was certified as a national laboratory on May 7, 2004.
Company Leadership BS
MF
AD
DH
SPL is a private equity-backed national provider of energy laboratory services, environmental testing, and measurement solutions headquartered in The Woodlands, Texas, with operations tracing back to 1944. The company serves energy producers, municipalities, industrial facilities, and environmental professionals, laboratory and field service locations throughout the United States. SPL's energy services include hydrocarbon laboratory analysis, gas and liquid measurement, production accounting, auditing, flow assurance studies, and allocation services supporting upstream, midstream, and downstream oil and gas operations. Its environmental testing capabilities cover drinking water, wastewater, groundwater, soil, and solid waste analysis, including specialty testing for PFAS, dioxins, and quaternary ammonium compounds. SPL combines ISO-certified laboratories, verifiable test methods, and patented software with digital workflows to deliver accurate, defensible data used for regulatory compliance, operational performance, and risk management. The company positions itself as a trusted partner for clients requiring reliable measurement and reporting across interconnected energy and environmental systems.
Company Leadership TG
WS
SG
Frequently Asked Questions Regarding Certara Top Executives and Leadership Team
